Bio-Path Holdings operates as a clinical and preclinical stage oncology focused antisense drug development company. The Company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. It has a number of drug candidates for the treatment of acute myeloid leukemia, chronic myelogenous leukemia, solid tumors and lymphoma.